Slide 1: Real-World Innovation: AI-first driven discovery platform
REAL -WORLD INNOVATION AI-first driven discovery platform - for multi parameter small -molecule generation June,162026
Slide 2: Forward Looking Statement
FORWARD This presentation contains "forward - looking statements" relating to future events, and Evogene Ltd. (the “Company ”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regard considered “forward
Slide 3: Evogene Pioneers Real-World Innovation
EVOGENE PIONEERS REAL -WORLD INNOVATION Using a proprietary generative AI engine, we generate novel and highly potent small molecules, optimized across -parameters, multiple for the pharmaceutical-chemical and ag industries 3
Slide 4: Our Story
OUR STORY PIONEERING IN PHARMA GEN AI ENGINE REVOLUTIONIZING AG Growing number of ChemPass AI - computational Proven strategic collaborations for a diverse engine for the generation & collaborations driving our pipeline of drug candidates optimization of small molecules ag- chem pipeline 4
Slide 5: The Discovery & Optimization Challenge
THE DISCOVERY & OPTIMIZATION CHALLENGE GENERATE THE RIGHT CANDIDATES TO REACH THE MARKET PRODUCT LESS THAN 10%OF PRODUCT CANDIDATE CANDIDATES TESTED IN CLINICAL TRIALS MAKE IT TO MARKET DISCOVERY & OPTIMIZATION TARGET SELECTION EARLY ADVANCED APPROVED (protein) DEVELOPMENT DEVELOPMENT PRODUCT HIT HI
Slide 6: Diverse Novel Chemical Structures & Multi-Parameter Challenge
DIVERSE NOVEL CHEMICAL STRUCTURES &- MULTI PARAMETER CHALLENGE Potency (Binding Affinity) The challenge - generate diverse Solubility small molecules with novel chemical structures that satisfy all required parameters defining the desired product, while proactively balancing multiple, often competin
Slide 7: ChemPass AI Breaking Chemical Space Limitation & Multi-Parameter Challenge
NOVEL CHEMICAL STRUCTURE - DRUG -LIKE, SYNTHESIZABLE MOLECULES Our AI engine generates novel compounds that are synthesizable and active, while accessing CHEMPASS AI unexplored chemical space and creating new IP opportunities BREAKING CHEMICAL SPACE LIMITATION &-PARAMETER MULTI MULTI -PARAMETER OPTI
Slide 8: ChemPass AI - Three Steps to Success
CHEMPASS AI - THREE STEPSTO SUCCESS Step1 Step2 Step3 Result HIT SCREENING HIT TO LEAD LEAD OPTIMIZATION EVOGENE TM PRODUCT CANDIDATE WITHPOINTHIT WITH TM ACTIVESEARCH LEADOP TM WITH GPT Utilizing deep learning to enhance rapid DMTA* coupled with upgraded analog Simultaneous optimization of multiple
Slide 9: Evogene's Unique Offering - Novel Chemistry That Works
EVOGENE ’S UNIQUE OFFERING – NOVEL CHEMISTRY THAT WORKS TM&ACTIVESEARCH POINTHIT TM - INTELLIGENCE: UNIQUE DATASET CREATION o Both POINTHIT TM & ACTIVESEARCH TM explore ultra - large vendor libraries ~ 70B molecules Deep understanding of the o POINTHIT TM utilizes virtual screening to generate a div
Slide 10: Technological Collaborations with Google Cloud
TECHNOLOGICAL COLLABORATION S WITH GOOGLE CLOUD FROM GENERATIVE MODELS TO AUTONOMOUS DISCOVERY FIRST COLLABORATION – FIRST -IN-CLASS FOUNDATION MODEL Successful completion of a proprietary generative AI model for novel molecular product candidates addressing multiple parameters, based on 38 billion
Slide 11: ChemPass AI - Generates Candidates for Commercial Success
CHEMPASS AI - GENERATES CANDIDATES FOR COMMERCIAL SUCCESS EVOGENE PRODUCT HIGHER PROBABILITY OF CANDIDATES SUCCESS DISCOVERY & OPTIMIZATION TARGET SELECTION EARLY ADVANCED APPROVED (protein) DEVELOPMENT DEVELOPMENT PRODUCT HIT HIT TO LEAD IDENTIFICATION LEAD OPTIMIZATION TM POINTHIT TM TM ACTIVESEAR
Slide 12: Business Strategy: Co-Development
BUSINESS STRATEGY CO-DEVELOPMENT - CAPTURE THE VALUE OF AITM CHEMPASS Unlock the full potential of ChemPass AITM through EVOGENE PARTNER strategic collaborative partnerships, accelerating AITM CHEMPASS SPECIFIC EXPERTISE innovation in small - molecule drug and agrochemical development NEW MOLECULAR
Slide 13: ChemPass AI Workflow
CHEMPASS AI WORKFLOW CHEMPASS AI DEVELOPMENT STEPS PARTNERINTERNAL / PIPELINE TARGET PREPROCESSING Preprocessing and target modeling TPP definition PointHit TM 1- HIT SCREENING Experimental validation Ultra large DB virtual screening ActiveSearch TM 2 - HIT-TO-LEAD Experimental validation ML enabled
Slide 14: Harnessing the Power of ChemPass AI for Real-World Innovation
HARNES SING THE POWER OF CHEMPASS -WORLD AI FOR REAL INNOVATION PHARMA DIVISION – DRUGS AG DIVISION* – AG-CHEMICALS COLLABORATIONS COLLABORATIONS Neutrophil- Derived Herbicides Inflammatory Diseases Demyelination Disorders INTERNAL PIPELINE Wheat Blotch Lung Cancer Metabolic Disease AG DIVISION* – O
Slide 15: Our Story
OUR STORY PIONEERING IN PHARMA GEN AI ENGINE REVOLUTIONIZING AG Growing number of ChemPass AI - computational Proven strategic collaborations for a diverse engine for the generation & collaborations driving our pipeline of drug candidates optimization of small molecules ag- chem pipeline 15
Slide 16: Growing Opportunity - AI Drug Discovery
PHARMA DIVISION GROWING OPPORTUNITY -DRUGIN DISCOVERY AI Account for AI-based candidates in pipeline Discovery market expected to SMALL 58% 1 >60 2 ~$190B 3 MOLECULES of total pharmaceutical market 1,344 B) ($ 150 % CAGR in 3last years by2034 16 1) DCAT Value Chain 2) Insights Science Direct 3) Prec
Slide 17: AI-First Compounds Under Development
PHARMA DIVISION AI-FIRST COMPOUNDS UNDER DEVELOPMENT 17
Slide 18: Potential Collaborators: Business & Development Strategy
PHARMA DIVISION POTENTIAL COLLABORATORS BUSINESS & DEVELOPMENT STRATEGY POTENTIAL PARTNERS UNMET NEEDS COMMON COLLABORATION PROFILE TIMELINE A strategic partnership to co - develop a novel drug 1. Rapid computational generation of molecules ACADEMIA/ asset, generate shared IP and/or commercializatio
Slide 19: Diversified Drug Discovery - Current Pipeline Status
PHARMA DIVISION DIVERSIFIED DRUG DISCOVERY – CURRENT PIPELINE STATUS LEAD INDICATION PROGRAM HIT ID HIT-TO-LEAD PRE-CLINICAL IND PARTNER OPTIMIZATION COLLABORATIONS Oncology EVG - O311 Undisclosed Metabolism* EVG - M410 Immunology EVG - I110 Neurology EVG - N210 Oncology EVG - O310 INTERNAL PIPELINE
Slide 20: Collaboration with Leading Academic Institute: Breast Cancer
PHARMA DIVISION COLLABORATIONAWITH LEADING ACADEMIC INSTITUTE (UNDISCLOSED) NOVEL THERAPIES FOR BREAST CANCER TREATMENT AND LONGEVITY • Target : novel key mechanism linked to cancer cell survival, migration and therapy resistance • Global breast cancer therapy market is estimated at $30- 37B annuall
Slide 21: PointHit - Superior Hit Rates of Highly Potent Molecules
TM- SUPERIOR HIT RATES OF HIGHLY POTENT MOLECULE POINTHIT 42molecules identified with outstanding results* “We used to screen thousands of compounds to get hits, with ChemPass AI this is not required. Out of 42 • 43% of tested considered candidate inhibitors compounds, 18 (43%) are inhibitors, and 8
Slide 22: Collaboration with Prof. Ehud Gazit, TAU: Metabolic Diseases
PHARMA DIVISION COLLABORATIONPROF. WITH EHUD GAZIT, TAU, -AVIV,TEL ISRAEL NOVEL THERAPEUTIC MODALITY FOR METABOLIC DISEASES • Target : molecular self- assembly metabolites that underlie metabolic conditions • Addressable Gout therapeutics market is evaluated at ~$3B* • Combines ChemPass AITM with un
Slide 23: ChemPass AI Results: Metabolic Diseases Collaboration
PHARMA DIVISION COLLABORATIONPROF. WITH EHUD GAZIT, TAU, -AVIV,TEL ISRAEL NOVEL THERAPEUTIC MODALITY FOR METABOLIC –CHEMPASSAITMDISEASES RESULTS 100 90 90 82 86 80 INTERMEDIATE ANALYSIS OF 15MOLECULES INITIAL 80 70 • 33% of tested compounds reach activity threshold % Inhibition 60 • 2 molecules outp
Slide 24: Our Story
OUR STORY PIONEERING IN PHARMA GEN AI ENGINE REVOLUTIONIZING AG Growing number of ChemPass AI - computational Proven strategic collaborations for diverse engine for the generation & collaborations driving our drug targets optimization of small molecules ag- chem pipeline 24
Slide 25: ~$88B Growing Market with Plenty of Room for Innovation
EVOGENE'S SUBSIDIARY ~$88B GROWING MARKET WITH PLENTY OF ROOM FOR INNOVATION $43.3B BROAD SPECTRUM 1 HERBICIDES UNMET NEEDS 1 Increase of pest resistance & regulatory requirements $22.2B FUNGICIDES FOR 2 Urgent need for new Modes of Action ( MoAs) 2 MAJOR DISEASES 3 Decreased rate in discovery of ne
Slide 26: Leading Crop Protection Companies
EVOGENE'S SUBSIDIARY LEADING CROP PROTECTION COMPANIES POTENTIAL DISCOVERY AND OUTLICENSE PARTNERS 26
Slide 27: Current Crop Protection Pipeline
EVOGENE'S SUBSIDIARY CURRENT CROP PROTECTION PIPELINE SAFETY AND FIELD PROGRA M INDICATION HIT ID HIT-TO-LEAD LEAD OPTIMIZATION PARTNER ENVIRONMENTAL TESTING COLLABORATIONS Herbicide APCO - 12 Stage confidential INTERNAL PIPELINE Fungicide APTF 1/APTF 4 27
Slide 28: Internal Pipeline: APTF-1 Wheat Blotch
EVOGENE'S SUBSIDIARY INTERNAL PIPELINE APTF -1PRESENTS STRONG POTENTIAL FOR REAL -WORLD INNOVATION WHEAT BLOTCH • Shows clear concentration - dependent antifungal efficacy DISRUPTING1.2 AB$PROBLEM AT RECORD SPEED • Ongoing optimization to • 70% of EU fungicide usage in wheat is for Wheat Blotch enha
Slide 29: End-to-End Process - Novel, Highly Potent, Optimized Molecules
EVOGENE'S SUBSIDIARY END -TO-END PROCESS – NOVEL, HIGHLY POTENT, OPTIMIZED MOLEC Step1 Step2 Step3 HIT SCREENING HIT TO LEAD LEAD OPTIMIZATION WITH TM POINTHIT TM WITH ACTIVESEARCH LEADOP TM WITH GPT TARGET PROTEIN New MOA - no available Ordered Ordered Ordered crystallographic structure with limite
Slide 30: Evogene - Looking Forward
EVOGENE – LOOKING FORWARD PHARMA DIVISION – DRUGS AG DIVISION* – AG-CHEMICALS • Progress in existing pipeline • Progress in existing pipeline • New collaborations with biotech companies • New collaborations with ag - chem and academic institutions companies • Building relationships with pharmaceutic
Slide 31: Generating Real-World Innovation
We generate highly potent and PIONEERING IN PHARMA NOVEL, DRUG -LIKE, novel small molecules, optimized Growing number of SYNTHESIZABLE MOLECULES across multiple - parameters, for collaborations addressing diverse drug targets for the pharmaceutical and ag - the benefit of human chemical industries h
Slide 32: Creating Real-World Innovation for a Better Future
Creating REAL-WORLD INNOVATION for a better future evOgene